Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer.
- Author:
Junhong DENG
1
;
Wanqing LI
;
Liuping YANG
;
Liangsheng WANG
;
Dehuan ZOU
Author Information
- Publication Type:Journal Article
- MeSH: Absorptiometry, Photon; Aged; Aged, 80 and over; Androgen Antagonists; therapeutic use; Bone Density; Humans; Male; Middle Aged; Orchiectomy; Osteoporosis; complications; physiopathology; Prostatic Neoplasms; complications; physiopathology; surgery
- From: National Journal of Andrology 2004;10(10):761-763
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo determine the influence of androgen deprivation therapy (ADT) on bone mineral density (BMD) in men with prostate cancer.
METHODSForty-nine men with prostate cancer underwent BMD determination and then were classified into two groups: non-ADT group (21 cases), who were about to receive ADT, and ADT group (28 cases), who had received ADT for more than 1 year. BMD was determined by dual energy X-ray absorptiometry (DEXA) in the lumbar spine (L2-4) and femoral neck in all the patients. The Age-Matched Z scores were used as the reference standard for controlling the difference of age, sex and weight.
RESULTSThirteen (62%) of the non-ADT group and 23 (82%) of the ADT group fulfilled the BMD criteria for osteopenia or osteoporosis. Z scores for the Age-Matched control in the lumbar spine and femoral neck were -(0.9 +/- 0.7) and -(0.6 +/- 0.5) in the non-ADT group, and -(1.8 +/- 1.1) and -(1.6 +/- 1.0) in the ADT group, respectively (P<0.01). The men of the ADT group had significantly lower BMD in the lumbar spine and femoral neck than those of the non-ADT group.
CONCLUSIONPre-existing osteopenia and osteoporosis are common in men with prostate cancer before ADT. ADT is significantly associated with the loss of BMD and the evaluation of BMD is necessary before ADT for men with prostate cancer.
